奥希替尼对比奥希替尼联合化疗用于EGFR T790M耐药后NSCLC的随机2期研究
这项开放标签随机2期研究纳入62例一线EGFR-TKI治疗后出现T790M耐药突变的EGFR突变阳性NSCLC患者,比较奥希替尼单药与奥希替尼联合卡铂-培美曲塞的疗效与安全性。
要点
- 联合组客观缓解率为53.6%,单药组为71.4%。
- 联合方案安全性总体可耐受,未观察到新的不良事件。
核心结论
- 在EGFR T790M耐药后的NSCLC二线治疗中,奥希替尼联合化疗未延长PFS,但总体可耐受。
研究设计与样本
- 开放标签随机2期研究,纳入62例一线EGFR-TKI治疗后出现T790M耐药突变的EGFR突变阳性NSCLC患者。
- 比较奥希替尼单药与奥希替尼联合卡铂-培美曲塞,主要终点为PFS。
主要发现
- 两组中位OS均未达到。
- 单药组客观缓解率为71.4%,联合组为53.6%。
- 联合组已知不良事件的频率或严重程度与既往报道的卡铂和培美曲塞相当,未观察到新发不良事件。
临床怎么用
- 对于EGFR T790M耐药后的NSCLC二线治疗,奥希替尼联合化疗未显示生存获益,不支持常规联合化疗。
- 联合方案总体可耐受,可在特定临床情境下考虑,但需进一步在一线 setting 中验证。
局限性
- 研究因奥希替尼在一线获批而提前终止招募,最终仅分析62例患者。
- 样本量较小,可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osimertinib is now a standard treatment for patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC). We here investigated whether the combination of osimertinib with cytotoxic chemotherapy might hold additive efficacy, as well as tolerability. PATIENTS AND METHODS: We conducted an open-label randomised phase 2 study to evaluate osimertinib and carboplatin-pemetrexed combination in comparison with osimertinib monotherapy in EGFR mutation-positive NSCLC patients who experienced disease progression associated with the emergence of the T790M resistance mutation of EGFR during first-line EGFR-TKI therapy. The primary endpoint was PFS, with secondary endpoints, including OS, response, and safety. Given that osimertinib was approved as a first-line treatment during the study, patient accrual was discontinued, and a final analysis was performed for the 62 enrolled patients. RESULTS: Median PFS was 15.8 months for the osimertinib monotherapy group and 14.6 months for the combination therapy group (hazard ratio of 1.09, with a 95% confidence interval of 0.51-2.32; P = .83). Median OS was not reached in either group. The overall response rate was 71.4% in the osimertinib monotherapy group and 53.6% in the combination group. The frequency or severity of known adverse events in the combination group was comparable to those with carboplatin and pemetrexed previously reported, and novel adverse events were not observed in this study. CONCLUSION: This is the first randomised study to investigate the efficacy and safety of the combination of osimertinib and cytotoxic chemotherapy for EGFR-mutated NSCLC. The addition of chemotherapy to osimertinib as a second-line treatment did not prolong survival, while it was found to be generally tolerable. This combination strategy will be further validated in the first-line setting. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) identifier: jRCTs071180062.
引用
- Tanaka K, Asahina H, Kishimoto J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. Eur J Cancer. 2021. PMID: 33813328. doi:10.1016/j.ejca.2021.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。